TY - JOUR T1 - Incidence of central serous chorioretinopathy (2011–2018): a nationwide population-based cohort study of Japan JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 1748 LP - 1753 DO - 10.1136/bjophthalmol-2021-319403 VL - 106 IS - 12 AU - Ai Kido AU - Masahiro Miyake AU - Hiroshi Tamura AU - Shusuke Hiragi AU - Takeshi Kimura AU - Shosuke Ohtera AU - Ayako Takahashi AU - Sotaro Ooto AU - Koji Kawakami AU - Tomohiro Kuroda AU - Akitaka Tsujikawa Y1 - 2022/12/01 UR - http://bjo.bmj.com/content/106/12/1748.abstract N2 - Aims The aim of this study was to elucidate the epidemiological background of central serous chorioretinopathy (CSC), including its incidence and treatment pattern.Methods This was a population-based longitudinal cohort study using a nationwide health insurance claims database of the Japan Ministry of Health, Labour and Welfare (MHLW). As Japan employs universal health coverage, the database covers more than 95% of claims issued in Japan. We accessed all data stored in the database with permission from the MHLW. We traced all individuals aged 30 years or older and identified individuals with new onset of CSC between January 2011 and December 2018. CSC cases were categorised by age and sex for each year, and incidence rate was calculated. We also identified major treatments for CSC to elucidate the initial treatment pattern.Results During the 8-year period, 247 930 incidences of CSC were identified, among which 75.9% were men. The crude incidence rate (per 100 000 person-years) in the general population aged 30 years or older was 34.0 (95% CI 33.9 to 34.2), in men was 54.2 (95% CI 53.9 to 54.4) and in women was 15.7 (95% CI 15.5 to 15.8). The mean age of onset was lower in men than in women (50.5±12.5 years vs 54.7±13.5 years). Most of the patients with newly diagnosed CSC (86.8%) did not receive major treatment.Conclusions The current study provides the nationwide population-based evidence to clarify the detailed epidemiology of CSC. These results could help to understand the pathogenesis and mechanisms of CSC in the future.Data may be obtained from a third party and are not publicly available. Data availability: The permission to access NDB expired after the authorised research period; therefore, we can no longer access the raw data without obtaining another access permission. The raw data can be accessed only after obtaining permission from the MHLW. Those who want to access raw data need to apply to the MHLW. The program codes used during the current study are available from the corresponding author on reasonable request. ER -